{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Targeted+agent&page=41", "query": { "intervention": "Targeted agent", "page": 41 }, "page_size": 10 }, "pagination": { "page": 41, "page_size": 10, "total_count": 1322, "total_pages": 133, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Targeted+agent&page=42&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Targeted+agent&page=40&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-05T02:12:59.543Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06597721", "title": "ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor", "PDAC", "HNSCC" ], "interventions": [ { "name": "ADCE-T02", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Adcendo ApS", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 210, "start_date": "2024-11-25", "completion_date": "2027-06-30", "has_results": false, "last_update_posted_date": "2026-09-09", "last_synced_at": "2026-11-05T02:12:59.543Z", "location_count": 7, "location_summary": "Rogers, Arkansas • New Haven, Connecticut • Boston, Massachusetts + 4 more", "locations": [ { "city": "Rogers", "state": "Arkansas" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06597721" }, { "nct_id": "NCT03654040", "title": "Liver Transplantation With Tregs at UCSF", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Liver Transplant" ], "interventions": [ { "name": "arTreg", "type": "BIOLOGICAL" }, { "name": "leukapheresis", "type": "PROCEDURE" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "mesna", "type": "DRUG" }, { "name": "everolimus", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 42, "start_date": "2021-04-22", "completion_date": "2023-03-06", "has_results": true, "last_update_posted_date": "2024-04-23", "last_synced_at": "2026-11-05T02:12:59.543Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03654040" }, { "nct_id": "NCT01561950", "title": "Efficacy of Activated Recombinant Human Factor VII in Healthy Volunteers Treated for Punch Biopsy Mediated Bleeding", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Haemostasis", "Healthy" ], "interventions": [ { "name": "eptacog alfa (activated)", "type": "DRUG" }, { "name": "clopidogrel", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "MALE", "summary": "18 Years to 45 Years · Male only" }, "enrollment_count": 91, "start_date": "2008-05", "completion_date": "2009-01", "has_results": false, "last_update_posted_date": "2016-11-23", "last_synced_at": "2026-11-05T02:12:59.543Z", "location_count": 1, "location_summary": "Neptune City, New Jersey", "locations": [ { "city": "Neptune City", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT01561950" }, { "nct_id": "NCT03724097", "title": "Identification of Molecular Biomarkers for Cancer Target Therapy Efficacy", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cancer" ], "interventions": [ { "name": "RNA sequencing", "type": "OTHER" }, { "name": "Transcriptome analysis", "type": "OTHER" }, { "name": "target drug with the score above 0,1", "type": "DRUG" }, { "name": "target drug with the score equal or below 0,1", "type": "DRUG" }, { "name": "non-target drug", "type": "DRUG" }, { "name": "palliative care", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "OmicsWay Corp.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 200, "start_date": "2017-10-17", "completion_date": "2022-11-01", "has_results": false, "last_update_posted_date": "2021-09-14", "last_synced_at": "2026-11-05T02:12:59.543Z", "location_count": 1, "location_summary": "Walnut, California", "locations": [ { "city": "Walnut", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03724097" }, { "nct_id": "NCT03153410", "title": "Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "GVAX Pancreas Vaccine (GVAX)", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "IMC-CS4", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2018-09-27", "completion_date": "2023-08-29", "has_results": true, "last_update_posted_date": "2025-01-09", "last_synced_at": "2026-11-05T02:12:59.543Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03153410" }, { "nct_id": "NCT07046923", "title": "A Study of LY4175408 in Participants With Advanced Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung", "Small Cell Lung Carcinoma", "Endometrial Neoplasms", "Neoplasm Metastasis", "Triple Negative Breast Cancer" ], "interventions": [ { "name": "LY4175408", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 240, "start_date": "2025-07-28", "completion_date": "2030-07", "has_results": false, "last_update_posted_date": "2026-06-23", "last_synced_at": "2026-11-05T02:12:59.543Z", "location_count": 15, "location_summary": "Stanford, California • Orlando, Florida • Sarasota, Florida + 11 more", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT07046923" }, { "nct_id": "NCT05621980", "title": "Finger Movement Training After Stroke", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Stroke" ], "interventions": [ { "name": "Actuated Virtual Keyboard (AVK) system", "type": "BEHAVIORAL" }, { "name": "Occupational Therapy (OT)", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "North Carolina State University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 10, "start_date": "2023-09-05", "completion_date": "2025-07-31", "has_results": false, "last_update_posted_date": "2026-08-20", "last_synced_at": "2026-11-05T02:12:59.543Z", "location_count": 1, "location_summary": "Raleigh, North Carolina", "locations": [ { "city": "Raleigh", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05621980" }, { "nct_id": "NCT01173146", "title": "Imaging of Residual Tumor During Prostatectomy", "overall_status": "WITHDRAWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Prostate Cancer" ], "interventions": [], "intervention_types": [], "sponsor": "Spectros Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "MALE", "summary": "Male only" }, "enrollment_count": 0, "start_date": "2011-12", "completion_date": "2015-06", "has_results": false, "last_update_posted_date": "2016-05-25", "last_synced_at": "2026-11-05T02:12:59.543Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01173146" }, { "nct_id": "NCT01726582", "title": "Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery (\"Personalized Medicine\")", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "Milestone 1: Targeted chemotherapy prior to surgery", "type": "DRUG" }, { "name": "Milestone 2: Chemoradiotherapy (cXRT)", "type": "RADIATION" }, { "name": "Milestone 3: Targeted chemotherapy prior to surgery", "type": "DRUG" }, { "name": "Milestone 3: Chemoradiotherapy (cXRT)", "type": "RADIATION" }, { "name": "Milestone 4: standard FOLFIRINOX chemotherapy prior to surgery", "type": "DRUG" }, { "name": "Milestone 4: Chemoradiotherapy (cXRT)", "type": "RADIATION" }, { "name": "Milestone 5: Targeted chemotherapy after surgery", "type": "DRUG" }, { "name": "Milestone 5: Chemoradiotherapy (cXRT)", "type": "RADIATION" }, { "name": "Milestone 6: Gemcitabine after surgery", "type": "DRUG" }, { "name": "Milestone 6: Chemoradiotherapy (cXRT)", "type": "RADIATION" }, { "name": "Milestone 7: Chemoradiotherapy (cXRT)", "type": "RADIATION" }, { "name": "Milestone 8: Targeted chemotherapy after surgery", "type": "DRUG" }, { "name": "Milestone 9: Gemcitabine after surgery", "type": "DRUG" }, { "name": "Milestone 10: No additional therapy after surgery", "type": "OTHER" } ], "intervention_types": [ "DRUG", "RADIATION", "OTHER" ], "sponsor": "Medical College of Wisconsin", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 229, "start_date": "2011-11", "completion_date": "2022-04-11", "has_results": true, "last_update_posted_date": "2023-08-14", "last_synced_at": "2026-11-05T02:12:59.543Z", "location_count": 2, "location_summary": "Cincinnati, Ohio • Milwaukee, Wisconsin", "locations": [ { "city": "Cincinnati", "state": "Ohio" }, { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT01726582" }, { "nct_id": "NCT05055323", "title": "A Study to Determine if the Drug, Pyrvinium Pamoate, is Safe and Tolerable in Patients With Pancreatic Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Resectable Pancreatic Ductal Adenocarcinoma", "Stage 0 Pancreatic Cancer AJCC v8", "Stage I Pancreatic Cancer AJCC v8", "Stage IA Pancreatic Cancer AJCC v8", "Stage IB Pancreatic Cancer AJCC v8", "Stage II Pancreatic Cancer AJCC v8", "Stage IIA Pancreatic Cancer AJCC v8", "Stage IIB Pancreatic Cancer AJCC v8" ], "interventions": [ { "name": "Pyrvinium Pamoate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Thomas Jefferson University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2021-07-29", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-07-21", "last_synced_at": "2026-11-05T02:12:59.543Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05055323" } ] }